BACKGROUND:Gemtuzumab ozogamicin (GO) is an active agent for the treatment of CD33-postive acute myeloid leukemia (AML) and may improve the outcome of specific patient subgroups when combined with conventional chemotherapy. However, to the best of the authors' knowledge, the effects of GO on levels of minimal residual disease (MRD) are unknown. METHODS:Pediatric patients with AML who receivedGO, either alone or in combination with chemotherapy on the AML02 multicenter trial, were analyzed to determine the effects of GO on MRD and outcome. RESULTS: Among 17 patients who receivedGO alone because of persistent leukemia, 14 had a reduction in their MRD level and 13 became MRD negative. Of the 29 who received chemotherapy in combination with GO after responding poorly to chemotherapy, 28 demonstrated reduced MRD and 13 became MRD negative. Treatment with GO effectively reduced MRD before hematopoietic stem cell transplantation and was not found to be associated with increased treatment-related mortality after transplantation. CONCLUSIONS:GO is effective in reducing MRD levels in pediatric patients with AML and may improve the outcome of those patients at high risk of disease recurrence.
RCT Entities:
BACKGROUND:Gemtuzumab ozogamicin (GO) is an active agent for the treatment of CD33-postive acute myeloid leukemia (AML) and may improve the outcome of specific patient subgroups when combined with conventional chemotherapy. However, to the best of the authors' knowledge, the effects of GO on levels of minimal residual disease (MRD) are unknown. METHODS: Pediatric patients with AML who received GO, either alone or in combination with chemotherapy on the AML02 multicenter trial, were analyzed to determine the effects of GO on MRD and outcome. RESULTS: Among 17 patients who received GO alone because of persistent leukemia, 14 had a reduction in their MRD level and 13 became MRD negative. Of the 29 who received chemotherapy in combination with GO after responding poorly to chemotherapy, 28 demonstrated reduced MRD and 13 became MRD negative. Treatment with GO effectively reduced MRD before hematopoietic stem cell transplantation and was not found to be associated with increased treatment-related mortality after transplantation. CONCLUSIONS:GO is effective in reducing MRD levels in pediatric patients with AML and may improve the outcome of those patients at high risk of disease recurrence.
Authors: E L Sievers; R A Larson; E A Stadtmauer; E Estey; B Löwenberg; H Dombret; C Karanes; M Theobald; J M Bennett; M L Sherman; M S Berger; C B Eten; M R Loken; J J van Dongen; I D Bernstein; F R Appelbaum Journal: J Clin Oncol Date: 2001-07-01 Impact factor: 44.544
Authors: Robert J Arceci; Jane Sande; Beverly Lange; Kevin Shannon; Janet Franklin; Raymond Hutchinson; Terry A Vik; David Flowers; Richard Aplenc; Mark S Berger; Matthew L Sherman; Franklin O Smith; Irwin Bernstein; Eric L Sievers Journal: Blood Date: 2005-05-10 Impact factor: 22.113
Authors: Ursula Creutzig; Martin Zimmermann; Thomas Lehrnbecher; Norbert Graf; Johann Hermann; Charlotte M Niemeyer; Alfred Reiter; Jörg Ritter; Michael Dworzak; Jan Stary; Dirk Reinhardt Journal: J Clin Oncol Date: 2006-09-20 Impact factor: 44.544
Authors: J Yates; O Glidewell; P Wiernik; M R Cooper; D Steinberg; H Dosik; R Levy; C Hoagland; P Henry; A Gottlieb; C Cornell; J Berenberg; J L Hutchison; P Raich; N Nissen; R R Ellison; R Frelick; G W James; G Falkson; R T Silver; F Haurani; M Green; E Henderson; L Leone; J F Holland Journal: Blood Date: 1982-08 Impact factor: 22.113
Authors: Martha Wadleigh; Paul G Richardson; David Zahrieh; Stephanie J Lee; Corey Cutler; Vincent Ho; Edwin P Alyea; Joseph H Antin; Richard M Stone; Robert J Soiffer; Daniel J DeAngelo Journal: Blood Date: 2003-05-08 Impact factor: 22.113
Authors: William J Kell; Alan K Burnett; Raj Chopra; John A L Yin; Richard E Clark; Ama Rohatiner; Dominic Culligan; Ann Hunter; Archie G Prentice; Donald W Milligan Journal: Blood Date: 2003-08-21 Impact factor: 22.113
Authors: J K Lamba; S Pounds; X Cao; J R Downing; D Campana; R C Ribeiro; C-H Pui; J E Rubnitz Journal: Leukemia Date: 2008-07-10 Impact factor: 11.528
Authors: Tracey A O'Brien; Susan J Russell; Marcus R Vowels; Cecilia M Oswald; Karin Tiedemann; Peter J Shaw; Liane Lockwood; Lochie Teague; Michael Rice; Glenn M Marshall Journal: Blood Date: 2002-10-15 Impact factor: 22.113
Authors: R J Wells; W G Woods; B C Lampkin; M E Nesbit; J W Lee; J D Buckley; C Versteeg; G D Hammond Journal: J Clin Oncol Date: 1993-03 Impact factor: 44.544
Authors: Jessica A Pollard; Michael Loken; Robert B Gerbing; Susana C Raimondi; Betsy A Hirsch; Richard Aplenc; Irwin D Bernstein; Alan S Gamis; Todd A Alonzo; Soheil Meshinchi Journal: J Clin Oncol Date: 2016-01-19 Impact factor: 44.544
Authors: Hiroto Inaba; Aditya H Gaur; Xueyuan Cao; Patricia M Flynn; Stanley B Pounds; Viswatej Avutu; Lindsay N Marszal; Scott C Howard; Ching-Hon Pui; Raul C Ribeiro; Randall T Hayden; Jeffrey E Rubnitz Journal: Cancer Date: 2014-03-26 Impact factor: 6.860
Authors: Thomas B Alexander; Lei Wang; Hiroto Inaba; Brandon M Triplett; Stanley Pounds; Raul C Ribeiro; Ching-Hon Pui; Jeffrey E Rubnitz Journal: Cancer Date: 2017-05-30 Impact factor: 6.860
Authors: Alan S Gamis; Todd A Alonzo; Soheil Meshinchi; Lillian Sung; Robert B Gerbing; Susana C Raimondi; Betsy A Hirsch; Samir B Kahwash; Amy Heerema-McKenney; Laura Winter; Kathleen Glick; Stella M Davies; Patti Byron; Franklin O Smith; Richard Aplenc Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544
Authors: Erin M Guest; Richard Aplenc; Lillian Sung; Susana C Raimondi; Betsy A Hirsch; Todd A Alonzo; Robert B Gerbing; Yi-Cheng Jim Wang; Samir B Kahwash; Amy Heerema-McKenney; Soheil Meshinchi; Alan S Gamis Journal: Blood Date: 2017-07-03 Impact factor: 22.113